Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Vaccine data
View:
Post by FarmerBetty on Apr 24, 2023 6:49pm

Vaccine data

For those wondering about the vaccine results show a robust antibody response against the ABO epitope was observed wtih both adjuvants and was remarkably maintained unabated out to 6 months after the last immunization. The serum antibodies reacted with ABO only, not monomers or plaque.

Conclusion a vaccine consisting of an ABO- restricted conformational B cell conjugated to KHL produced a strong Abeta antibody response with no measurable pro-inflammatory T cell response against Abeta. In addition, the oligomer selectivity of the antibodies focused the response on pathogenic ABO, portentially reducing the risk of ARIA-E associated with binding to plaque and vascular deposits of Abeta.
Comment by goldtech on Apr 24, 2023 9:24pm
Farmer Betty do I take this post as an acknowledgement that we are on the right track? I know where your coming from and yes it's been years of corporate mismanagement, but let's give Gail some time and see. Great post by the way.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities